Emergent BioSolutions | EBS - Actif À Court Terme





Actif À Court Terme Changement Date
Acadia Pharmaceuticals USD 1.06B 14.31M 2025-12
Akebia Therapeutics USD 252.96M 5.38M 2025-12
ALKERMES USD 1.93B 187.5M 2025-12
Alnylam Pharmaceuticals USD 4.05B 97.85M 2025-12
Amarin USD 628.33M 21.52M 2025-09
ANI Pharmaceuticals USD 753.12M 54.72M 2025-12
BioMarin Pharmaceutical USD 3.95B 98.95M 2025-12
Coherus Biosciences USD 206.71M 254.25M 2025-12
Emergent BioSolutions USD 679.5M 41.3M 2023-12
Exact Sciences USD 1.56B 34.88M 2025-12
Exelixis USD 1.44B 41.03M 2025-12
Glaxosmithkline GBP 23.98B 6.31B 2025-09
Heron Therapeutics USD 229.4M 18.48M 2025-09
Ionis Pharmaceuticals USD 2.99B 471.01M 2025-12
Ironwood Pharmaceuticals USD 273.84M 82.09M 2025-09
Lexicon Pharmaceuticals USD 145.08M 100.72M 2025-06
Lonza CHF 5.44B 113M 2024-12
Merck USD 47.56B 10.49B 2025-09
Moderna USD 6.54B 54M 2025-12
Myriad Genetics USD 344.8M 60.5M 2025-09
Nektar Therapeutics USD 281.36M 94.79M 2025-09
Neurocrine Biosciences USD 2.52B 364.3M 2025-12
Pacira USD 547.97M 14.78M 2025-12
Pfizer USD 46.92B 3.22B 2025-09
PTC Therapeutics USD 2.27B 266.14M 2025-12
Sanofi EUR 30.95B 3.09B 2025-12
Sarepta Therapeutics USD 2.54B 184.37M 2025-12
United Therapeutics USD 3.7B 208.5M 2025-12
Vanda Pharmaceuticals USD 347.26M 20.23M 2025-12
Xoma USD 110.71M 5.78M 2025-09